Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
26/08/2026 08:33
BRIEF-Nxera Pharma Co., Ltd.- Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition Aug 26 (Reuters) - Nxera Pharma Co., Ltd. 4565.T:
NXERA PHARMA CO., LTD.: NXERA PHARMA'S PARTNER NEUROCRINE BIOSCIENCES RECEIVES IND ACCEPTANCE FROM FDA FOR PHASE 2 STUDY OF NBI-1117567 FOR ALZHEIMER'S COGNITION
NXERA PHARMA CO., LTD.: PARTNER NEUROCRINE BIOSCIENCES RECEIVED IND ACCEPTANCE FROM U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR A PHASE 2 STUDY OF NBI-1117567 FOR ALZHEIMER'S COGNITION
NXERA PHARMA CO., LTD.: NXERA WILL RECEIVE AN IND ACCEPTANCE MILESTONE PAYMENT OF US$10 MILLION FROM NEUROCRINE PURSUANT TO AGREEMENT
NXERA PHARMA CO., LTD.: MILESTONE PAYMENT IS EXPECTED TO BE RECOGNISED IN FULL AS REVENUE IN Q3 FY2026
Source text: ID:nTStz808cd
Further company coverage: 4565.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall